Latest Research And Development News

TALi Digital (ASX:TD1) is raising up to $3.3 million through a Security Purchase Plan and Placement to fund its acquisition of Datasphere Analytics and advance its AI-driven education platform.

CurveBeam AI has secured over A$600,000 through its Share Purchase Plan, bolstering funds alongside a recent A$5 million placement. The capital will fuel the China launch and product development for its HiRise™ CT scanner.

Cycliq Group Limited reported a 20.7% revenue decline to AUD 3.79 million for FY2026, but reduced its net loss by 83% to AUD 85,897, driven by disciplined cost control and strategic platform investments.

Invex Therapeutics posted a $1.35 million net loss for FY2026, driven by expanded R&D efforts and a deepening collaboration with Tessara Therapeutics targeting neurological diseases including Alzheimer’s. The company renewed its orphan drug status in Europe and restructured its board during the year.

Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.

Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.

Nimy Resources reports metallurgical tests achieving 84% gallium and up to 95% rare earth extraction at its Mons Project Block 3, underpinning proprietary processing technology and feeding into a scoping study.

Streamplay Studio Limited surged past $13 million in revenue for FY26, driven by a full year of Noodlecake Studios' contribution, while trimming its net loss by 15%.

Audeara Limited delivered record FY26 revenue of $4.45 million, driven by a 45% surge in Australian wholesale sales and progress in AI audio licensing with OPTEK Microelectronics. The company narrowed its loss and advanced Auracast deployments across retirement villages and education sectors.

Ion Video Limited narrowed its loss to $4.52 million in FY2026, slashing operating costs and shifting focus to intellectual property licensing while strengthening its balance sheet and securing funding through to late 2027.

IODM Limited’s FY26 results show solid revenue gains led by UK education, but losses persist with a net deficiency in equity raising going concern questions.

Ceretas Limited posted a $1.63 million net loss for FY26 on $1.28 million revenue from government grants, advancing its clinical-stage Alzheimer’s ultrasound platform. The company completed an $8 million IPO in July to fund pivotal trials and device development.